» Articles » PMID: 19843847

ATAD2 is a Novel Cofactor for MYC, Overexpressed and Amplified in Aggressive Tumors

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Oct 22
PMID 19843847
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

The E2F and MYC transcription factors are critical regulators of cell proliferation and contribute to the development of human cancers. Here, we report on the identification of a novel E2F target gene, ATAD2, the predicted protein product of which contains both a bromodomain and an ATPase domain. The pRB-E2F pathway regulates ATAD2 expression, which is limiting for the entry into the S phase of the cell cycle. We show that ATAD2 binds the MYC oncogene and stimulates its transcriptional activity. ATAD2 maps to chromosome 8q24, 4.3 Mb distal to MYC, in a region that is frequently found amplified in cancer. Consistent with this, we show that ATAD2 expression is high in several human tumors and that the expression levels correlate with clinical outcome of breast cancer patients. We suggest that ATAD2 links the E2F and MYC pathways and contributes to the development of aggressive cancer through the enhancement of MYC-dependent transcription.

Citing Articles

FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer.

Rida P, Baker S, Saidykhan A, Bown I, Jinna N Cancers (Basel). 2024; 16(18).

PMID: 39335162 PMC: 11429756. DOI: 10.3390/cancers16183191.


Correlations between C-myc expression, BMI-1 expression, and vaginal microecology with HPV-DNA load in patients with different cervical lesions.

Zhou Y, Zhu J, Zhang H Am J Transl Res. 2024; 16(6):2544-2553.

PMID: 39006286 PMC: 11236621. DOI: 10.62347/GPLZ1377.


Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains.

Phillips M, Malone K, Boyle B, Montgomery C, Kressy I, Joseph F J Med Chem. 2024; 67(10):8186-8200.

PMID: 38733345 PMC: 11149620. DOI: 10.1021/acs.jmedchem.4c00210.


Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.

Lee P, Koseki L, Haitani T, Harada H, Kobayashi M Cancers (Basel). 2024; 16(9).

PMID: 38730681 PMC: 11083728. DOI: 10.3390/cancers16091729.


Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.

Naik A, Lattab B, Qasem H, Decock J Mol Ther Oncol. 2024; 32(1):200768.

PMID: 38596293 PMC: 10876628. DOI: 10.1016/j.omton.2024.200768.